The association between use of antidepressants and bone quality using quantitative heel ultrasound

Australian and New Zealand Journal of Psychiatry

Volumn 49, Issue 5, 2015, Pages 437-443

  Rauma, Päivi H ^a   Pasco, Julie A ^b,c   Berk, Michael ^a,c   Stuart, Amanda L ^b   Koivumaa Honkanen, Heli ^{a,d,e,f,g,h,i}   Honkanen, Risto J ^a   Hodge, Jason M ^b,j   Williams, Lana J ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF OULU   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f NORTH KARELIA CENTRAL HOSPITAL   (Finland)

^g SOSTERI   (Finland)

^h SOTE   (Finland)

ⁱ LAPLAND CENTRAL HOSPITAL   (Finland)

^j GEELONG HOSPITAL   (Australia)

more..

Author keywords

antidepressants; bone mineral density; bone quality; osteoporosis; selective serotonin reuptake inhibitors

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CALCIUM; CITALOPRAM; DESVENLAFAXINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; PAROXETINE; SERTRALINE; VENLAFAXINE; VITAMIN D;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BONE DENSITY; BROADBAND ULTRASOUND ATTENUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET SUPPLEMENTATION; ECHOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; PHYSICAL ACTIVITY; SIDE EFFECT; SOCIAL STATUS; SPEED OF SOUND; STIFFNESS INDEX; WEIGHT REDUCTION; AUSTRALIA; BODY WEIGHT; DEPRESSION; DRUG EFFECTS; FOLLOW UP; HEEL; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; SELF REPORT; STATISTICAL MODEL; VERY ELDERLY;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; AUSTRALIA; BODY WEIGHT; BONE DENSITY; CROSS-SECTIONAL STUDIES; DEPRESSION; FOLLOW-UP STUDIES; HEEL; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; SELF REPORT;

EID: 84930155527     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414565475     Document Type: Article

References (50)

1. Blanchflower DG and Oswald AJ (2011) Antidepressants and age. IZA Discussion paper No. 5785.
2. Bliziotes M (2010) Update in serotonin and bone. The Journal of Clinical Endocrinology and Metabolism 95: 4124-4132.
3. Bolton JM, Targownik LE, Leung S, et al. (2011) Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. Journal of Clinical Psychopharmacology 31: 56-60.
4. Brennan SL, Henry MJ, Nicholson GC, et al. (2009) Socioeconomic status and risk factors for obesity and metabolic disorders in a populationbased sample of adult females. Preventive Medicine 49: 165-171.
5. Britt H, Miller GC, Charles J, et al. (2010) General practice activity in Australia 2009-10. General Practice Series No. 27 (Cat. no. GEP 27). Canberra: AIHW
6. Calarge CA, Zimmerman B, Xie D, et al. (2010) A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. Journal of Clinical Psychiatry 71: 338-347.
7. Cauley JA, Fullman RL, Stone KL, et al. (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporosis International 16: 1525-1537.
8. Center JR, Nguyen TV, Schneider D, et al. (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156): 878-882.
9. Diem SJ, Blackwell TL, Stone KL, et al. (2007) Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Archives of Internal Medicine 167: 1240-1245.
10. Diem SJ, Ruppert K, Cauley JA, et al. (2013) Rates of bone loss among women initiating antidepressant medication use in midlife. The Journal of Clinical Endocrinology and Metabolism 98(11): 4355-4363.
11. Finnish Medicines Agency Fimea and Social Insurance Institution (2012) Finnish Statistics on Medicines 2012. Helsinki: Edita Prima O.y.
12. First M, Spitzer R, Gibbon M, et al. (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Research version, non-patient edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute
13. Giles C and Ireland P (1996) Dietary Questionnaire for Epidemiological Studies (Version 2). Melbourne: The Cancer Council Victoria
14. Gold PW and Chrousos GP (2002) Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Molecular Psychiatry 7: 254-275.
15. Haentjens P, Magaziner J, Colón-Emeric CS, et al. (2010) Meta-analysis: Excess mortality after hip fracture among older women and men. Annals of Internal Medicine 152: 380-390.
16. Haney EM, Chan BK, Diem SJ, et al. (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Archives of Internal Medicine 167: 1246-1251.
17. Henry MJ, Pasco JA, Nicholson GV, et al. (2011) Prevalence of osteoporosis in Australian men and women: Geelong Osteoporosis Study. Medical Journal of Australia 195: 321-322.
18. Hodge JM, Wang Y, Berk M, et al. (2013) Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biological Psychiatry 74: 32-39.
19. Jacka FN, Pasco JA, Henry MJ, et al. (2005) Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study. Menopause 12: 88-91.
20. Jacka FN, Pasco JA, Henry MJ, et al. (2007) Depression and bone mineral density in a community sample of men: Geelong Osteoporosis Study. The Journal of Men's Health and Gender 4: 292-297.
21. Jordan KM and Cooper C (2002) Epidemiology of osteoporosis. Best Practice & Research: Clinical Rheumatology 16: 795-806.
22. Kinjo M, Setoguchi S, Schneeweiss S, et al. (2005) Bone mineral density in subjects using central nervous system-active medications. The American Journal of Medicine 118: 1414.
23. Laugier P (2004) An overview of bone sonometry. International Congress Series 1274: 23-32.
24. Mezuk B, Eaton WW, Golden SH, et al. (2008a) Depression, antidepressants, and bone mineral density in a population-based cohort. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 63: 1410-1415.
25. Mezuk B, Eaton WW and Golden SH (2008b) Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporosis International 19: 1-12.
26. Moura C, Bernatsky S, Abrahamowicz M, et al. (2014) Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporosis International 25: 1473-1481.
27. National Center for Health Statistics (2011) Health, United States, 2010: With Special Feature on Death and Dying. Available at: http://www. cdc.gov/nchs/data/hus/hus10.pdf
28. Organization for Economic Co-operation and Development (2013) Antidepressants consumption, 2000 and 2011 (or nearest year). In: Health at a Glance. Paris: OECD Publishing. DOI: 10.1787/health-glance-2013-graph93-en
29. Otmar R, Kotowicz MA, Brennan SL, et al. (2013) Personal and psychosocial impacts of clinical fracture in men. Journal of Men's Health 10: 22-27.
30. Pasco JA, Nicholson GC and Kotowicz MA (2012) Cohort profile: Geelong Osteoporosis Study. International Journal of Epidemiology 41: 1565-1575.
31. Pasco JA, Sanders KM, Hoekstra FM, et al. (2005) The human cost of fracture. Osteoporosis International 16: 2046-2052.
32. Prieto-Alhambra D., Petri H., Goldenberg JSB, et al. (2014) Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA. Osteoporosis International 25: 847-855.
33. Pye SR, Devakumar V, Boonen S, et al. (2010) Influence of lifestyle factors on quantitative heel ultrasound measurements in middle-aged and elderly men. Calcified Tissue International 86: 211-219.
34. Richards JB, Papaioannou A, Adachi JD, et al. (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Archives of Internal Medicine 167: 188-194.
35. Seifert CF and Wiltrout TR (2013) Calcaneal bone mineral density in young adults prescribed selective serotonin reuptake inhibitors. Clinical Therapeutics 35: 1412-1417.
36. Spangler L, Scholes D, Brunner RL, et al. (2008) Depressive symptoms, bone loss, and fractures in postmenopausal women. Journal of General Internal Medicine 23: 567-574.
37. Teng GG, Curtis JR and Saag KG (2008) Mortality and osteoporotic fractures: is the link causal, and is it modifiable?. Clinical and Experimental Rheumatology 26(Suppl. 51): S125-S137.
38. Warden SJ, Robling AG, Sanders MS, et al. (2005) Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146: 685-693.
39. Williams LJ, Bjerkeset O, Langhammer A, et al. (2011) The association between depressive and anxiety symptoms and bone mineral density in the general population: the HUNT study. Journal of Affective Disorders 131: 164-171.
40. Williams LJ, Henry MJ, Berk M, et al. (2008) Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. International Clinical Psychopharmacology 23: 84-87.
41. Williams LJ, Pasco JA, Jacka FN, et al. (2009) Depression and bone metabolism: A review. Psychotherapy and Psychosomatics 78: 16-25.
42. Woolcott JC, Richardson KJ, Wiens MO, et al. (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Archives of Internal Medicine 169: 1952-1960.
43. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group. World Health Organization Technical Report Series 843: 1-129.
44. World Health Organization (2007) WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Summary Meeting Report, Brussels, Belgium, 5-7 May 2004. Geneva: WHO Press. Available at: http://www.who.int/chp/topics/Osteoporosis.pdf
45. World Health Organization (2008) The Global Burden of Disease: 2004 Update. Geneva: WHO Press
46. Wu Q, Bencaz AF, Hentz JG, et al. (2012) Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporosis International 23: 365-375.
47. Wu Q, Qu W, Crowell MD, et al. (2013) Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies. Journal of Bone and Mineral Research 28: 753-763.
48. Yadav VK, Oury F, Suda N, et al. (2009) A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138: 976-989.
49. Yadav VK, Ryu J-H, Suda N, et al. (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135: 825-837.
50. Yirmiya R and Bab I (2009) Major depression is a risk factor for low bone mineral density: a meta-analysis. Biological Psychiatry 66: 423-432.